Professor of Medicine, University MD School of Medicine
Hematology
Dr. Aaron P. Rapoport, MD
|
|
Give Review
Dr. Aaron P. Rapoport is an expert in the field of Hematology. He went to medical school at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification", "America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore" and "Super Doctor". Aaron P. Rapoport, MD is a published physician as well. He has 92 publications published. The latest was: Autotransplantation for relapsed or refractory Hodgkin''s disease: long-term follow-up and analysis of prognostic factors. Dr. Aaron P. Rapoport is registered with Medicare and accepts Medicare payments.
Publications
- Major clinical response to nivolumab in relapsed/refractory Hodgkin Lymphoma after allogeneic stem cell transplantation.
- NY-ESO-1-specific TCR-engineered T Cells mediate sustained antigen-specific antitumor effects in myeloma.
- TLR5 ligand-secreting T Cells reshape the tumor microenvironment and enhance antitumor activity.
- Disparities in black and white patients with multiple Myeloma referred for autologous hematopoietic transplantation: A single center study.
- Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autolo...
- Survival analysis with functional covariates for partial follow-up studies.
- Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism.
- Donating used CARs.
- Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem Cell transplantation (SCT) in patie...
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T Cells in myeloma and melanoma.
- Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid Leukemias.
- c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant Lymphomas.
- Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
- Plasma exchange and rituximab treatment for lenalidomide-associated cold agglutinin Disease.
- Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis.
- Successful treatment of IgG and complement-mediated autoimmune hemolytic Anemia with bortezomib and low-dose cyclophosphamide.
- Combination immunotherapy using adoptive T-Cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
- Transfer of influenza vaccine-primed costimulated autologous T Cells after stem Cell transplantation for multiple myeloma leads to reconstitution of influenza immunity...
- Rapid immune recovery and graft-versus-host Disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.
- Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell Lymphoma combination therapy.
- Neurotoxicity of bortezomib therapy in multiple Myeloma: a single-center experience and review of the literature.
- Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53.
- Treatment and outcomes of post-transplant lymphoproliferative Disease: a single institution study.
- Large cell Lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency.
- Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem Cell mobilization in patients with multiple myeloma.
- Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-Cell transfer.
- Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple Myeloma patients.
- Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (Cellcept) in advanced multiple myeloma patients.
- Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) Acute myeloid leukemia: two case reports and a review of literature.
- Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic Cells.
- Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A.
- Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma.
- Minocycline treatment in Acute stroke: an open-label, evaluator-blinded study.
- Increased cerebrospinal fluid glutamine levels in depressed patients.
- [Clinical and epidemiological characteristics of squamous Cell carcinoma of the oral cavity in women].
- Treatment of status epilepticus and Acute repetitive seizures with i.v. valproic acid vs phenytoin.
- Orthotopic liver transplantation for life-threatening veno-occlusive Disease of the liver after allogeneic bone marrow transplant.
- Laboral outcome after Acute unilateral vestibulopathy.
- Therapeutic association for nasopharyngeal cancer.
- Oral sumatriptan for the long-term treatment of migraine: clinical findings.
- A 78-year-old man with Pancytopenia and abnormal lymphocytes.
- Plasma Cell dyscrasia in a 15-year-old boy: case report and review of the literature.
- [Exclusive radiotherapy and radiotherapy-intra-arterial chemotherapy combination in the treatment of advanced cancer of the oropharynx. Retrospective study of 126 cases].
- Cardiac arrest after autologous marrow infusion.
- Hemopoietic growth factors: a review.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor biology, signal transduction, and neutrophil acti...
- Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist.
- Chronic inflammatory demyelinating polyneuropathy in non-Hodgkin's Lymphoma.
- Mutational analysis of the alpha subunit of the human interleukin-3 receptor.
- Life-threatening autoimmune hemolytic Anemia in a patient with the acquired immune deficiency syndrome.
- REL-positive double minute chromosomes in follicular Lymphoma.
- A fatal Clostridium infection in an allogeneic stem Cell transplant recipient.
- Treatment of multifocal Lymphoma of bone with intensified ProMACE-CytaBOM chemotherapy and involved field radiotherapy.
- Immunity for tumors and microbes after autotransplantation: if you build it, they will (not) come.
- Sequence analysis and functional studies of interleukin-3 receptor alpha subunit-encoding cDNAs amplified from KG-1 leukemic Cells and normal human marrow.
- Leukocyte-reduced transfusions of ABO-identical platelets and clinical outcome in autologous bone marrow transplantation for Lymphoma.
- Detection of MOZ-CBP fusion in Acute myeloid leukemia with 8;16 translocation.
- Treatment of relapsed or refractory Hodgkin disease and non-Hodgkin Lymphoma with high-dose chemoradiotherapy followed by unstimulated autologous peripheral stem cell ...
- Autotransplantation for advanced Lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
- Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
- Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years.
- Autotransplantation for relapsed or refractory non-Hodgkin''s Lymphoma (NHL): long-term follow-up and analysis of prognostic factors.
- Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin Lymphoma.
- Amifostine and autologous hematopoietic stem Cell support of escalating-dose melphalan: a phase I study.
- Autotransplantation for relapsed or refractory Hodgkin''s Disease: long-term follow-up and analysis of prognostic factors.
- Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem Cell transplantation.
- Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T Cells.
- Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin''s Lymphoma.
- Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's Lymphoma cell line containing mutant p53 genes.
- Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
- One hundred autotransplants for relapsed or refractory Hodgkin's disease and Lymphoma: value of pretransplant disease status for predicting outcome.
- Leukodepleted-ABO-identical blood components in the treatment of hematologic malignancies: a cost analysis.
- Treatment of chronic myelogenous Leukemia with autologous bone marrow transplantation followed by roquinimex.
- Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-Cell transplants.
- Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell Lymphoma.
- Fatal disseminated adenoviral infection associated with thrombotic Thrombocytopenic purpura after allogeneic bone marrow transplantation.
- PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
- High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor Cells in patients with multiple myeloma: efficacy and toxicity.
- Autologous stem Cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
- Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host Disease prophylaxis after allogeneic transplant...
- Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing Disease after autotransplantation.
- PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's Lymphoma and other highly proliferative malignant cells.
- Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and Lymphoma.
- Osteonecrosis of the jaw in multiple Myeloma patients: clinical features and risk factors.
- Flavonoid effects on normal and leukemic Cells.
- Timed sequential therapy of Acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinosi...
- Catastrophic antiphospholipid syndrome: atypical presentation in the setting of Chronic graft versus host disease: case report and review of the literature.
- Expression of PDZ-binding kinase (PBK) is regulated by Cell cycle-specific transcription factors E2F and CREB/ATF.
- Persistent positron emission tomography positivity secondary to benign histiocytic proliferation after treatment of Hodgkin Lymphoma.
- Detection of CD4(+) T-Cell antibodies in a patient with idiopathic CD4 T lymphocytopenia and cryptococcal meningitis.
- Primary gastric T cell Lymphoma mimicking marginal zone B cell Lymphoma of mucosa-associated lymphoid tissue.
Schools
Harvard Medical School
Strong Memorial Hospital
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Burkitt's Lymphoma
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Super Doctor
Education
-
University of Rochester -
Harvard Medical School
Hospital
-
University of Maryland Baltimore Washington Medical Center -
University of Maryland Medical Center
Drug Facts
| NPI NUMBER | 1356309280 | |
| NPPES Provider LastName | RAPOPORT | |
| NPPES Provider FirstName | AARON | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology | |
| Total Claim Count | 286.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 4.2 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356309280 |
| Last Name Of The Provider | RAPOPORT |
| First Name Of The Provider | AARON |
| View All |
Similar Doctors
|
|
Dr. Peter C. Agre, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michael Auerbach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy E. Dezern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry Waterbury, MD |
|
|
Dr. Leisha A. Emens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan D. Powell, MD |
|
|
Dr. Robert A. Brodsky, MD |
|
|
Dr. Saul Yanovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy S. Kimball, MD |
|
|
Dr. Milena Vuica-Ross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. McDevitt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nitya P. Raj, MD |
|
|
Daniel Kejzman |
|
|
Adrian G. Murphy, MB CHB |